Standout Papers
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. (1998)
Citation Impact
Citing Papers
Diabetes and Cardiovascular Disease
1999 Standout
Role of Genotype in the Cycle of Violence in Maltreated Children
2002 StandoutScience
Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC)
2007
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
2010
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
2008
Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
2016
Actos Now for the prevention of diabetes (ACT NOW) study
2009
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018
Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
2016
Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: a randomised controlled trial
2015
Improving the Quality of Chronic Disease Management for Populations with Low Functional Health Literacy: A Call to Action
2001
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
2014
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Pathogenesis of type 2 diabetes mellitus
2004
Abdominal obesity and metabolic syndrome
2006 StandoutNature
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
2000
Exploring the characteristics of suboptimally controlled patients after 24 weeks of basal insulin treatment: An individualized approach to intensification
2016
Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
2015
Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study
2002
Inflammation and metabolic disorders
2006 StandoutNature
Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes
2010
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland
1999
What Do We Know and We Do Not Know About Cardiovascular Autonomic Neuropathy in Diabetes
2012
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
2008
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
2007 Standout
The Quality of Health Care Delivered to Adults in the United States
2003 Standout
Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
2008
Adjustable Gastric Banding and Conventional Therapy for Type 2 Diabetes
2008
Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children
2016 Standout
Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials
2014
Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway
2002 StandoutNobel
Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice
2003
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
2013
Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
2017 Standout
Molecular Defects in Insulin Secretion in Type-2 Diabetes
2004
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
2000 Standout
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
2016
Hypoglycemia in Patients With Type 2 Diabetes Mellitus
2001
Point of care testing
2001
Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors
2010
Insulin resistance and cardiovascular disease
2000
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials
2006
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
2006
Epigenetic phenomena linked to diabetic complications
2010
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
2009
Comparable myelinated nerve pathology in feline and human diabetes mellitus
2007
Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
2010
Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells
2011
Diabetic neuropathy: clinical manifestations and current treatments
2012
Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort
2009
Global and societal implications of the diabetes epidemic
2001 StandoutNature
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis
2005
Diabetes structured self-management education programmes: a narrative review and current innovations
2017
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Mechanisms linking obesity to insulin resistance and type 2 diabetes
2006 StandoutNature
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
2013
Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice
2005
Patient-Important Outcomes in Registered Diabetes Trials
2008
Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
2007
Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000
2003
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
2006
Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality
1999
Rosiglitazone RECORD study: glucose control outcomes at 18 months
2007
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
2008
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Do sulphonylureas still have a place in clinical practice?
2018
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1α and VEGF
2002
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
2017
Diabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes
2014
Biochemistry and molecular cell biology of diabetic complications
2001 StandoutNature
Antithrombotic Therapy in Peripheral Arterial Disease
2008
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Association of Health Literacy With Diabetes Outcomes
2002 Standout
Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance
2001 Standout
The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle, and Metabolic Risk Factors
2009 Standout
Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications
2003
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
2004
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
2017
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
2017
Diabetic neuropathy: cellular mechanisms as therapeutic targets
2011
Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)
2001
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2015
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
2009
Redefining Type 2 diabetes: ‘Diabesity’ or ‘Obesity Dependent Diabetes Mellitus’?
2000
Microfluidic diagnostic technologies for global public health
2006 StandoutNature
Hyperlipidemia: a new therapeutic target for diabetic neuropathy
2009
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same?
2000
Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy
2003
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus
2006
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
2011
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
2010
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
2003 Standout
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
2017
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
2017
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells
2003
Metabolic syndrome: Definition, pathophysiology, and mechanisms
2005
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
2009
Glycemic Control, Complications, and Death in Older Diabetic Patients
2011
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
2011
Dissecting racial bias in an algorithm used to manage the health of populations
2019 StandoutScience
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
2009 Standout
Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus
1999
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the E fficacy and D urability of I nitial C ombination T herapy for T ype 2 D iabetes ( EDICT ): a randomized trial
2014
Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone
2001
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
2001
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
2008 Standout
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus
2007
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
Fasting and Postchallenge Glycemia and Cardiovascular Disease Risk
2002
Type 2 diabetes: principles of pathogenesis and therapy
2005 Standout
Effect of Candesartan on Microalbuminuria and Albumin Excretion Rate in Diabetes
2009
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis
2010
Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus
2004 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Impaired insulin secretion and glucose intolerance in synaptotagmin-7 null mutant mice
2008 StandoutNobel
Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
1985 Standout
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes
2005 Standout
Oxidative Stress and Diabetic Complications
2010 Standout
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
2007
Health care and health status and outcomes for patients with type 2 diabetes.
2000
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
2002 Standout
Intensive glucose control and macrovascular outcomes in type 2 diabetes
2009
Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology
2006
Effects of Different Modes of Exercise Training on Glucose Control and Risk Factors for Complications in Type 2 Diabetic Patients
2006
Cardiac Autonomic Neuropathy in Diabetes
2010
The role of oxidative stress in the onset and progression of diabetes and its complications: asummary of a Congress Series sponsored byUNESCO-MCBN, the American Diabetes Association and the German Diabetes Society
2001
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
2015
Pharmacologic Therapy for Type 2 Diabetes Mellitus
1999
Diabetes Mellitus
2000
Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations
1999
Synthesis of an organoinsulin molecule that can be activated by antibody catalysis
2001 StandoutNobel
β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats
2001
Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes
2015
Intensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus
2003
Effect of Reinstitution of Good Glycemic Control on Retinal Oxidative Stress and Nitrative Stress in Diabetic Rats
2003
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study
1999
Association Between Impaired Cardiovascular Autonomic Function and Hypoglycemia in Patients With Type 1 Diabetes
2014
Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes
2009
Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
2010
Mechanisms of Diabetic Complications
2013 Standout
Effects of Exercise on Cardiovascular Risk Factors in Type 2 Diabetes
2011
Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3)
2014
A Diabetes Report Card for the United States: Quality of Care in the 1990s
2002
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
2011
Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-analysis
2017
Diabetes and Arterial Extracellular Matrix Changes in a Porcine Model of Atherosclerosis
2007
Effects of Intensive Glucose Lowering in Type 2 Diabetes
2008 Standout
Glucosamine-Induced Endoplasmic Reticulum Dysfunction Is Associated With Accelerated Atherosclerosis in a Hyperglycemic Mouse Model
2006
Diabetic Neuropathy: A Position Statement by the American Diabetes Association
2016 Standout
Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes
2003 Standout
Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk
2004
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin
2011
New Drugs for the Treatment of Diabetes
2008
Prevalence of Neuropathy and Peripheral Arterial Disease and the Impact of Treatment in People With Screen-Detected Type 2 Diabetes
2011
Initiating Insulin Therapy in Type 2 Diabetes
2005
Adjust to Target in Type 2 Diabetes
2008
Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort
2013
Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
2011
Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus
2014
Gut hormone PYY3-36 physiologically inhibits food intake
2002 StandoutNature
Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice
2002
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
2005
Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes
2008
The Diabetes Quality Improvement Project
2001
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
The Treat-to-Target Trial
2003 Standout
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
2012
Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
2002 Standout
Status of Hemoglobin A1c Measurement and Goals for Improvement: From Chaos to Order for Improving Diabetes Care
2010
Works of Matthews being referenced
LOSS OF NORMAL SIGMOID, BETA-CELL DOSE-RESPONSE CURVE TO GLUCOSE IN NON-INSULIN-DEPENDENT DIABETES
1984
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
1998 Standout